Amgen’s Innovative Study on AMG 193 for Advanced Thoracic Tumors: A Market Perspective

Amgen Inc ((AMGN)) announced an update on their ongoing clinical study.

Amgen Inc. is conducting a Phase 1b clinical study titled ‘AMG 193 Alone or in Combination With Other Therapies in Subjects With Advanced Thoracic Tumors With Homozygous MTAP-deletion (Master Protocol).’ The study aims to determine the maximum tolerated dose and safety profile of AMG 193, a PRMT5 inhibitor, in combination with other therapies for patients with advanced MTAP-deleted thoracic tumors. This research is significant as it explores new treatment avenues for a challenging cancer subtype.

The study tests AMG 193, administered orally, both alone and in combination with other drugs such as carboplatin, paclitaxel, pembrolizumab, pemetrexed, and sotorasib. These interventions target non-small cell lung cancer (NSCLC) with specific genetic mutations, aiming to improve patient outcomes.

The study design is interventional, non-randomized, with a parallel assignment model and no masking. Its primary purpose is treatment, focusing on evaluating the safety and efficacy of the drug combinations.

The study began on September 17, 2024, with its primary completion and estimated completion dates yet to be announced. The latest update was submitted on August 13, 2025. These timelines are crucial for tracking the study’s progress and potential market entry.

This study update could influence Amgen’s stock performance positively by showcasing its commitment to innovative cancer therapies. It may also affect investor sentiment, especially if the results show promise. Competitors in the oncology space will be watching closely as advancements in this area can shift market dynamics.

The study is ongoing, and further details can be found on the ClinicalTrials portal.